Year: 2020

Millennial Lithium Corp. Receives Government Approval for Its Environmental Impact Assessment for Construction and Operations for Its Pastos Grandes Project, Salta, Argentina

MotherlodeTV
V.ML, Millenial Lithium, lithium, Argentina

Millennial Lithium Corp. (TSXV: ML) (FSE: A3N2) (OTCQX: MLNLF) (“Millennial” or the “Company”) is pleased to report that its wholly owned subsidiary, Proyecto Pastos Grandes S.A. (“PPGSA”), has received a Declaracion de Impacto Ambiental (the “DIA”) from the Environmental and Mining Authority in Salta Province, Argentina. The DIA represents the Environmental and Mining Authority’s approval of PPGSA’s Environmental Impact Assessment (the “EIA”) for Construction and Operation of a 24,000 tonne per year battery grade lithium carbonate production facility at its flagship Pastos Grandes lithium carbonate project. The DIA is the main environmental approval document required for mining projects in Salta Province to both proceed to the construction stage and to operate. The Pastos Grandes Project is currently the only active pre-construction phase project in the region with this key milestone permit. read more

GR Silver Mining Reports High-Grade Silver-Gold Drill Results at Plomosas

11.0 m at 1,235 gpt Ag, including 2.3 m at 2,600 gpt Ag and 1.7 m at 4,209 gpt Ag
MotherlodeTV
V.GRSL, GR Silver Mining, silver, gold, Mexico
Figure 1: Drone Image of the Plomosas Mine Area (looking to the NW) (CNW Group/GR Silver Mining Ltd.)
Figure 1: Drone Image of the Plomosas Mine Area (looking to the NW) (CNW Group/GR Silver Mining Ltd.)

GR Silver Mining Ltd. (TSXV: GRSL), (FRANKFURT: GPE), (OTCQB: GRSLF) (“GR Silver Mining” or the “Company”) – is pleased to announce drill results at its 100%-owned Plomosas Silver Project (“Plomosas Project”) in Sinaloa, Mexico. These results are located in the Plomosas Mine Area, one of six priority areas with a combination of recent (2016 to 2018) and historical drill data being released by the Company. read more

FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA

All subjects completed the trial per protocol, no safety concerns found up to the highest dose tested of 2400 mg/day
MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced favorable topline results from its Phase 1 randomized, double-blind, placebo-controlled study of ultramicronized palmitoylethanolamide (PEA), or FSD201. This single-site study was conducted at the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in Australia and enrolled 48 healthy adult men and women. read more

GR Silver Mining Completes $9,153,000 Bought Deal Financing

MotherlodeTV
V.GRSL, GR Silver Mining, silver, gold, Mexico

GR Silver Mining Ltd. (TSXV: GRSL) (FRANKFURT: GPE) (OTCQB: GRSLF) (“GR Silver Mining” or the “Company”) – is pleased to announce that it has completed its previously announced bought deal private placement (the “Offering“) of an aggregate of 33,900,000 units of the Company (the “Units“) at a price of $0.27 per Unit (the “Issue Price“) for gross proceeds of $9,153,000, which included the exercise of the underwriters’ option in full. Each Unit consists of one common share in the capital of the Company and one-half of one common share purchase warrant (each whole warrant, a “Warrant“). Each Warrant is exercisable to acquire one common share of the Company at an exercise price of $0.40 per share for a period of 12 months from the closing date of the Offering. read more

White Gold Corp. Announces Closing of Fully Subscribed C$6 Million Private Placement Led by Eric Sprott; Agnico Eagle and Kinross Maintain 17.1% Interest

MotherlodeTV
V.WGO, White Gold, gold, Yukon

Further to its news release dated May 15, 2020, White Gold Corp. (TSX.V: WGO, OTC – Nasdaq Intl: WHGOF, FRA: 29W) (the “Company”) is pleased to announce the closing of a non-brokered private placement of 6,666,667 common shares (the “FT Shares”) of the Company, issued on a flow-through basis at a price of C$0.90 per FT Share for gross proceeds to the Company of C$6,000,000 (the “Offering”). Participants include Eric Sprott, certain funds managed by Sprott Asset Management LP, and insiders Pat DiCapo and David D’Onofrio. Upon closing of the Offering, the Company will have net working capital of approximately C$9M. read more

FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (the “Company”) announces the closing of a previously announced private placement of 1,500,000 of the Company’s Class B Subordinate Voting Shares (“Shares”) at a price of C$6.75 per Share and warrants to purchase 1,500,000 Shares (cumulatively, the “Securities”) of the Company to certain institutional investors for gross proceeds, before deducting placement fees and other estimated offering expenses payable by the Company, of approximately C$10.125 million. The warrants have a five-year term and an exercise price of C$9.65 per share. read more

FSD Pharma Inc. Announces C$10.125 Million Private Placement

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (NASDAQ: HUGE) CSE;HUGE or the “Company”), today announced it has entered into definitive agreements with certain institutional investors for the purchase and sale of 1,500,000 shares of the Company’s Class B Subordinate Voting Shares (“Shares”) at a price of C$6.75 per Share pursuant to a private placement resulting in gross proceeds of approximately C$10.125 million. The Company has also agreed to issue common share purchase warrants to purchase 1,500,000 Shares of the Company. The warrants will have a five year-term and an exercise price of C$9.65 per share. The closing of the offering is expected to occur on or about June 8, 2020, subject to the satisfaction of customary closing conditions including applicable exchange approvals.  The Company has granted the investors an option to acquire up to an additional C$10.125 million of units on the terms set forth above for a period of 30 days following the initial closing. read more

FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA)  to treat COVID-19, the disease caused by the SARS-CoV-2 virus. Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. FSD Pharma is focused on developing FSD-201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients. read more